Categories Uncategorized

Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science

  • The publication provides a comprehensive analysis of proteins from human blood plasma that interact with CNM-Au8(R)
  • CNM-Au8 nanocrystals coated with a protein corona are less prone to clumping compared to those without any coating
  • Certain apolipoproteins found on the nanocrystals’ surface, which aid in crossing the blood-brain barrier (“BBB”), were identified, suggesting an enhanced delivery mechanism into the brain
  • The findings enrich the understanding of CNM-Au8’s mechanism as preparations for a Phase 3 trial for ALS are underway, scheduled for the second half of 2024

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently reported the publication of “Protein Corona Composition of Gold Nanocatalysts” in the journal ACS Pharmacology & Translational Science, a journal of the American Chemical Society that publishes research with translational relevance across a broad spectrum of biological sciences (https://ibn.fm/JPS7Z).

A research team led by Morteza Mahmoudi, an associate professor at Michigan State University’s Precision Health program and Department of Radiology, along with his lab members, have provided a comprehensive analysis of proteins from human blood plasma that interact with the gold nanocrystals of CNM-Au8(R), a drug currently under investigation for treating neurodegenerative conditions.

CNM-Au8 consists of clean-surfaced gold nanocrystals that are ingested and absorbed into the bloodstream, where they bond with proteins and other biomolecules to form what is known as a ‘protein/biomolecular corona’. Utilizing advanced techniques perfected by Prof. Mahmoudi’s lab, the researchers were able to detail the makeup of this protein corona around CNM-Au8 nanocrystals, making several key discoveries:

  • CNM-Au8 nanocrystals coated with this protein corona are less prone to clumping compared to those without any coating
  • Certain apolipoproteins found on the nanocrystals’ surface, which aid in crossing the BBB, were identified, suggesting an enhanced delivery mechanism into the brain
  • The composition of the protein corona, notably lacking in enrichment of complement proteins and fibrinogens but enriched for specific apolipoproteins, suggests improved stability in suspension and reduced potential for immune response, potentially lengthening their presence in the bloodstream

The study is available for review at https://pubs.acs.org/doi/full/10.1021/acsptsci.4c00028.

Prof. Mahmoudi highlighted the unique composition of the CNM-Au8 gold nanocrystals’ protein corona, particularly the enhanced presence of key apolipoproteins like apolipoprotein E, facilitating its passage through the BBB. The absence of certain proteins extends the nanocrystals’ bloodstream lifespan, aligning with clinical observations. This engineered structure, free of surfactants, aids in delivering the nanocrystals to brain tissue effectively.

Mark Mortenson, Chief Science Officer of Clene, reflected on the development of these gold nanocrystals, noting the initial focus on their catalytic properties but recognizing the significance of the protein corona in controlling the nanocrystals’ in vivo biodistribution. The findings support the beneficial properties of CNM-Au8 as a neuroprotective agent, corroborated by preclinical and clinical research outcomes.

Michael Hotchkin, Clene’s Chief Development Officer, reported consistency in the favorable effects of orally administered CNM-Au8 on brain metabolites in Phase 2 trials for MS and Parkinson’s disease. Safety and tolerability were confirmed across extensive trials, with the formation of the protein corona once in the bloodstream playing a crucial role in enhancing brain accessibility. The findings enrich the understanding of CNM-Au8’s mechanism as preparations for a Phase 3 trial for ALS are underway, scheduled for the second half of 2024.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Wastewater Provides Vital Clues on Community Health Patterns, Study Finds

A study conducted recently in Ohio has found that wastewater can be a vital provider…

3 days ago

Preclinical Study Suggests New Therapy Could Wipe Out Brain Tumors

UC San Francisco-based scientists have developed a new immunotherapy that was successful in wiping out…

4 days ago

MIT Researchers Engineer Donor Immune Cells to Wipe Out Cancer Cells

Immunotherapy has transformed cancer treatment, but the approach still faces challenges like lengthy preparation time…

6 days ago

Expert Explains Why Healthcare Costs are Continuing to Rise in the US

The palpable euphoria surrounding the election of Democratic healthcare professionals to key positions in the…

1 week ago

Study Finds That High-Risk Antibiotic is Given to 20% of Patients Having Dental Infections

When a person develops a serious dental infection, the pain can be excruciating, particularly when…

2 weeks ago

Adaptogenics Health Corp. (CSE: ADPT) Eyes Opportunities Beyond Standard Peptides as Policy Opens Pharmacy and Telehealth Channels

Disseminated on behalf of Adaptogenics Health Corp.and may include paid advertising. The federal government is…

2 weeks ago